Operationalizing Bioethics in Pharma
Our team of bioethicists and analysts are dedicated to advancing patient and global health, by ensuring pharma innovates responsibly and puts patients first.
Our team of bioethicists and analysts are dedicated to advancing patient and global health, by ensuring pharma innovates responsibly and puts patients first.
We are one for everyone—one organization to develop, monitor and disseminate industry benchmarks, and better the efforts and wellbeing of all healthcare stakeholders. We are one meeting place for physicians, patients, regulators, and pharmaceutical companies to come to the table to discuss what works, what needs improvement, and most importantly, where we can go together.
Bioethics International (BEI) was co-founded in 2005, by Dr. Jennifer E. Miller to advance ethics and patient-centricity in medicine. BEI was incorporated as a 501c3 in the State of New York in 2006 and awarded public charity status by the IRS in 2007. We publicly launched the Good Pharma Scorecard (GPS) at a multi-stakeholder meeting in NYC in 2009. Our first set of GPS rankings, were released in partnership with Harvard University’s Edmond J. Safra Center for Ethics, in 2015. Today, the charity has grown to include a great team of researchers, advisors, and directors and a vast network of representatives from foundations, industry, patient groups, government, academia, and socially responsible investors.
BEI publishes its 5th Good Pharma Scorecard, rating sponsors on their transparent and representative enrollment of women, older adults and racial and ethnic minoritized patients in pivotal trials for novel oncology therapeutics approved by the FDA in 2012-2017. The 2023 GPS newly includes DEI measures and company ratings , for the 1st time.
BEI publishes its 4th Good Pharma Scorecard, ranking sponsors of new drugs approved by the FDA in 2016-2017, on their clinical trial transparency and data sharing performance. The 2021 GPS newly includes small and medium sized companies in the rankings, for the first time
BEI publishes its 3rd Good Pharma Scorecard, ranking new drugs approved by the FDA in 2015, and their large pharma company sponsors, on clinical trial transparency and data sharing. BEI develops and adds new data-sharing measures to the rankings, for the first time
BEI publishes its 2nd Good Pharma Scorecard, ranking the clinical trial transparency of drugs approved by the FDA in 2014, sponsored by large companies. BEI adds a new Pharma Company Ranking to the GPS, for the first time
BEI hosts a Patient Roundtable to discuss ethics and patient centricity in pharma
BEI partners with E&Y to host its 17th pharmaceutical executive roundtable on ethics, trust, and the Good Pharma Scorecard
Laura and John Arnold Foundation awards BEI a $3.6 million grant to expand the Good Pharma Scorecard
BEI releases its 1st Good Pharma Scorecard, a pilot in partnership with Harvard University, ranking the transparency of drugs approved by the FDA in 2012. BMJ Open votes the publication an ‘Editors’ Pick’ for 2015. It was one of their ‘Most Popular Articles’ of the year. More than 40 news outlets cover the rankings
MIT and Harvard host a hackathon for the Good Pharma Scorecard and ICorruption projects
Duke University awards a fellowship in regulatory governance to BEI’s founder, Jennifer Miller, to help think through governance models for the Good Pharma Scorecard and BEI
BEI partners with Harvard Medical School to co-host a conference on Global Health Footprint labeling
BEI partners with Harvard University’s Ethics Center to refine and pilot the Good Pharma Scorecard. BEI hosts several pharma executive and multi-stakeholder roundtables on the state of ethics and trust in the pharma industry
Raskob Foundation awards a grant to BEI to create ethics metrics for the pharma industry that will serve as the basis of the Good Pharma Scorecard
BEI co-hosts a conference with Princeton University and Fordham University on finding common ground on contentious public health issues. The conference is supported by the Ford Foundation and several others
BEI hosts an ethics panel for the Biotechnology Industry Organization’s International Convention. Experts from Pfizer, Yale, and Faster Cures discussed: Who Should be Responsible for Tomorrow’s Drugs?
Susan G. Komen Foundation provides visionary grant to BEI to begin developing pharma ethics standards and exploring the creation of a pharma ethics accreditation or rating system. The standards eventually form part of the Good Pharma Scorecard
BEI hosts its first multi-stakeholder meeting, at GoodwinProcter, on ethics and trust in pharma and whether an ethics accreditation, certification, rating, or ranking system could help
BEI co-hosts a United Nations affiliated conference on New Dilemmas in Medicine: Current Controversies in Genetics, Religion, and Big Pharma
IRS grants public charity status to BEI. BEI develops emergency preparedness and disaster response education programs for clinicians and hospitals that are implemented in hospitals along the East Coast of the United States. Dr. Miller, BEI’s founder, is appointed an advisor to the AMA’s National Disaster Life Support Education Consortium
BEI is incorporated in the State of New York as a 501C3 nonprofit under the auspices of three founding board members. BEI’s first aim is to develop an ethics framework to empower clinicians and researchers to make responsible and people-centered decisions
BEI was founded by Dr. Jennifer E. Miller to advance ethics, trustworthiness and patient-centricity in medicine